Accelerating Clinical Evidence Synthesis with Large Language Models

Zifeng Wang¹, Lang Cao¹, Benjamin Danek¹, Yichi Zhang¹, Qiao Jin², Zhiyong Lu², Jimeng Sun^{1,3#}

 1 Department of Computer Science, University of Illinois Urbana-Champaign, Champaign, IL

 2 National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD

³ Carle Illinois College of Medicine, University of Illinois Urbana-Champaign, Champaign, IL #Corresponding authors. Emails: jimeng@illinois.edu

Abstract

Automatic medical discovery by AI is a dream of many. One step toward that goal is to create an AI model to understand clinical studies and synthesize clinical evidence from the literature. Clinical evidence synthesis currently relies on systematic reviews of clinical trials and retrospective analyses from medical literature. However, the rapid expansion of publications presents challenges in efficiently identifying, summarizing, and updating evidence. We introduce TrialMind, a generative AI-based pipeline for conducting medical systematic reviews, encompassing study search, screening, and data extraction phases. We utilize large language models (LLMs) to drive each pipeline component while incorporating human expert oversight to minimize errors. To facilitate evaluation, we also create a benchmark dataset TrialReviewBench, a custom dataset with 870 annotated clinical studies from 25 meta-analysis papers across various medical treatments. Our results demonstrate that TrialMind significantly improves the literature review process, achieving high recall rates (0.897-1.000) in study searching from over 20 million PubMed studies and outperforming traditional language model embeddings-based methods in screening (Recall@20 of 0.227-0.246 vs. 0.000-0.102). Furthermore, our approach surpasses direct GPT-4 performance in result extraction, with accuracy ranging from 0.65 to 0.84. We also support clinical evidence synthesis in forest plots, as validated by eight human annotators who preferred TrialMind over the GPT-4 baseline with a winning rate of 62.5%-100% across the involved reviews. Our findings suggest that an LLM-based clinical evidence synthesis approach, such as TrialMind, can enable reliable and high-quality clinical evidence synthesis to improve clinical research efficiency.

Introduction

Clinical evidence is crucial for supporting clinical practices and advancing new drug development. It is primarily gathered through retrospective analysis of real-world data or through prospective clinical trials that assess new interventions on humans. Researchers often conduct systematic reviews to consolidate evidence from various studies in the literature.¹ However, conducting a systematic literature review is expensive and time-consuming, requiring five experts to analyze 195 publications over 67 weeks on average.² Moreover, the fast growth of clinical study databases means that the information in these published clinical reviews becomes outdated rapidly.³ This situation underscores the urgent need to streamline the systematic review processes to produce systematic and timely clinical evidence from the extensive medical literature.⁴

Large language models (LLMs) excel at information processing and generating, showing great promise in streamlining the clinical evidence synthesis process. Adapting LLMs to new tasks can be done by providing them the task definition and examples as the text inputs (namely 'prompts') without the need of retraining the model.⁵ Researchers have tried to adopt LLMs for individual tasks in literature review.^{6–10} For example, by enhancing inputs with multiple papers, LLMs can summarize findings to answer medical questions.⁹ This strategy helps reduce hallucinations but still faces challenges when the input studies do not adequately support the posed questions, which requires more effort in literature search and screening steps. Furthermore, LLMs often demonstrate limitations in reasoning with numerical data found in clinical studies. The qualitative clinical evidence generated using raw paper content via prompting can be overly generic, lack critical information, or misinterpret results.¹¹ Therefore, we propose developing an LLMdriven pipeline to assist the entire workflow, including formulating research questions, conducting literature mining, extracting information, and synthesizing clinical evidence. This includes a comprehensive evaluation of LLMs in the entire process, which was not well-explored.¹²

This study aims to fulfill the potential of AI in helping medical practitioners with the entire clinical evidence synthesis process using AI. We demonstrate how our method **TrialMind** is optimized for the clinical evidence synthesis task via: (1) generating boolean queries to search from the literature; (2) building inclusion and exclusion criteria to screen through the found studies; (3) extracting key information, including study protocols, methods, participant baselines, etc., from unstructured documents, per users' request; and (4) synthesizing high-quality clinical evidence. Unlike previous approaches, **TrialMind** integrates LLMs into an AI pipeline by breaking down the task into multiple steps that align with expert practices. This approach maintains flexibility by involving humans in the loop to monitor, edit, and verify all intermediate steps and the final synthesized outputs.

This paper curated a benchmark dataset TrialReviewBench for a comprehensive evaluation. The dataset includes 870 involved clinical studies and more than 50,000 identified studies from 25 meta-analyses. It also consists of manual annotations of 1,334 study characteristics and 1,049 study results. We show that the TrialMind is able to 1) retrieve a complete list of target studies from the literature, 2) follow the specified eligibility criteria to rank the most relevant studies at the top, and 3) achieve high accuracy in extracting information and clinical outcomes from unstructured documents based on user requests. Additionally, the extracted clinical outcomes can be standardized as input for meta-analysis (e.g., forest plots). We conducted a human evaluation of the synthesized evidence to demonstrate the potential value of TrialMind in practice.

Results

Creating TrialReviewBench from medical literature

A systematic understanding of cancer treatments is crucial for oncology drug discovery and development. Using a large list of cancer treatments from the National Cancer Institute (NCI),¹³ we curated a dataset TrialReviewBench of systematic reviews. To ensure data



Figure 1: The TrialMind framework has four components: a) Utilizing input PICO elements, TrialMind generates key terms to construct Boolean queries for retrieving studies from literature databases. b) TrialMind formulates eligibility criteria, which users can edit to provide context for LLMs during eligibility predictions. Users can then select studies based on these predictions and rank their relevance by aggregating them. c) TrialMind processes the descriptions of target data fields to extract and output the required information as structured data. d) TrialMind extracts findings from the studies and collaborates with users to synthesize the clinical evidence.

quality, we crafted comprehensive queries with automatic filtering and manual screening. For each review, we obtained the list of studies with their PubMed IDs, retrieved their full content, and extracted study characteristics and clinical outcomes. We followed PubMed's usage policy and guidelines during retrieval. Further manual checks were performed to correct inaccuracies, eliminate invalid and duplicate papers, and refine the text for clarity (Methods). The final TrialReviewBench dataset consists of 870 studies involved in 25 reviews (Fig. 2a), including (1) Brachytherapy:^{14–16} 3 reviews with 189 involved studies and 5.811 identified studies; (2) Chemotherapy: $^{17-19}$ 3 reviews with 126 involved studies and 5,874 identified studies; (3) Hyperthermia: 20-22 3 reviews with involved 28 studies and 5.972 identified studies; (4) Hormone Therapy: $^{23-25}$ 3 reviews with 30 involved studies and 5,970 identified studies; (5) Cancer Vaccine:²⁶ one review with 6 involved studies and 1,994 related studies; (6) Immune Checkpoint Inhibitors:^{27–29} 3 reviews with 187 involved studies and 5,813 identified studies; (7) Immune System Modulators:³⁰ one review with 9 involved studies and 1,991 identified studies; (8) Monoclonal Antibodies:³¹⁻³³ 3 reviews with 228 involved studies and 5,772 identified studies; (9) T-cell Transfer Therapy:^{34,35} 2 reviews with 36 involved studies and 3.964 identified studies; (10) Stem Cell Transplant:^{36–38} 3 reviews with 31 involved studies and 5,969 identified studies. The detailed characteristics of these studies are in Extended Table 1.

Build an LLM-driven system for clinical evidence synthesis

Large language models (LLMs) excel in adapting to new tasks when provided with taskspecific prompts while often struggling with complex tasks that require multi-step reasoning. Additionally, interacting and collaborating with LLMs can be problematic due to their opaque nature and the complexity of debugging.³⁹ In this study, we developed **TrialMind** that decomposes the clinical evidence synthesis process into four main tasks (Fig. 1 and Methods). Initially, using the provided research question enriched with population, intervention, comparison, and outcome (PICO) elements, **TrialMind** conducts a comprehensive search from the literature. It also works with users to build the criteria for study screening and rank the studies. Next, **TrialMind** browses the study details to extract the study characteristics and pertinent findings. To ensure the accuracy and integrity of the data, each output is linked to the sources for manual inspection. In the final step, **TrialMind** standardizes the clinical outcomes for meta-analysis.

TrialMind can make a comprehensive retrieval of studies from the literature

Finding relevant studies from medical literature like PubMed, which contains over 37 million entries, can be challenging. Typically, this requires the research expertise to craft complex queries that comprehensively cover pertinent studies. The challenge lies in balancing the specificity of queries: too stringent, and the search may miss relevant studies; too broad, and it becomes impractical to manually screen the overwhelming number of results. Previous approaches propose to prompt LLMs to generate the searching query in one pass,⁶ which can induce incomplete searching results due to the limited knowledge of LLMs. In contrast, **TrialMind** is designed to produce comprehensive queries through a pipeline that includes query generation, augmentation, and refinement. It also provides users with the ability to make adjustments (Fig. 2b).

The dataset involving clinical studies spanning ten cancer treatment areas was used for evaluation (Fig. 2a). For each review, we collected the involved studies' PubMed IDs as the ground-truth and measured the Recall, i.e., how many ground-truth studies are found in the search results. We created two baselines as the comparison: GPT-4 and Human. The GPT-4 baseline makes a guided prompt for LLMs to generate the boolean queries.⁶ It represents the common way of prompting LLMs for literature search query generation. The Human baseline represents a way where the key terms from PICO elements are extracted manually and expanded, referring to UMLS,⁴⁰ to construct the search queries.

Overall, TrialMind achieved a Recall of 0.921 on average for all reviews in TrialReviewBench, meaning it can capture all target studies most of the time. By contrast, the GPT-4 base-



Figure 2: Literature search experiment results. a, Total number of involved studies and participants of the review papers across different topics. b, The TrialMind's interface for users to retrieve studies. c, The Recall of the search results for reviews across four topics. The bar heights indicate the Recall, and the star indicates the number of studies found. d, Scatter plots of the Recall against the number of ground-truth studies. Each scatter indicates the results of one review. Regression estimates are displayed with the 95% CIs in blue or purple.

line yielded Recall = 0.079, and the Human baseline yielded Recall = 0.230. We divided the search results across four topics determined by the treatments studied in each review (Fig. 2c). Our analysis showed that TrialMind can identify many more studies than the baselines. For instance, TrialMind achieved Recall = 0.914 (N studies = 28,863) for Immunotherapy-related reviews, while the GPT-4 baseline got Recall = 0.1 (N studies = 22), and the Human baseline got Recall = 0.154 (N studies = 153), respectively. In Radiation/Chemotherapy, TrialMind achieved Recall = 0.897, the GPT-4 baseline got Recall = 0.017, and the Human baseline got Recall = 0.304. In Hormone Therapy, TrialMind achieved Recall = 0.924, the GPT-4 baseline got Recall = 0.100, and the Human baseline got Recall = 0.150. In Hyperthermia, TrialMind achieved Recall = 1.000, the GPT-4 baseline got Recall = 0.133, and the Human baseline got Recall = 0.683. These results demonstrate that regardless of the search task's complexity, as indicated by the variability in the Human baseline, TrialMind consistently retrieves nearly all target studies from the PubMed database. This robust performance provides a solid foundation for accurately identifying target studies in the screening phase.

Furthermore, we made scatter plots of Recall versus the number of target studies for each review (Fig. 2d). The hypothesis was that an increase in target studies correlates with the difficulty of achieving complete coverage. Our findings reveal that TrialMind consistently maintained a high Recall, nearing 1 in many instances and never falling below 0.7, significantly outperforming the best baselines across all 25 reviews. A trend of declining Recall with an increasing number of target studies was confirmed through regression analysis. For example, with fewer than 20 target studies, TrialMind achieved perfect Recall for most reviews, while the GPT-4 baseline struggled, showing Recall close to 0, and the Human baseline results varied between 0 and 0.85. As the number of target studies increased, the Human and GPT-4 baselines' Recall decreased to nearly zero. In contrast, TrialMind demonstrated remarkable resilience, showing minimal variation in performance despite the increasing number of target studies. For instance, in a review involving 141 studies, TrialMind achieved a Recall of 0.99, while the GPT-4 and Human baselines obtained a Recall of 0.02 and 0, respectively.

TrialMind enhances literature screening and ranking

Typically, human experts manually sift through thousands of retrieved studies to select relevant ones for inclusion in a systematic review. This process adheres to the PRISMA statement,⁴¹ which involves creating a list of eligibility criteria and assessing each study's eligibility. TrialMind streamlines this task through a three-step approach: (1) it generates a set of inclusion criteria, which are subject to user's adjustments; (2) it applies these criteria to evaluate the study's eligibility, denoted by $\{-1, 0, 1\}$ where -1 and 1 represent eligible and non-eligible, and 0 represents unknown/uncertain, respectively; and (3) it ranks the studies by aggregating the eligibility predictions, where the aggregation strategy can be specified by users (Fig. 3a). We took a summation of the criteria-level eligibility predictions as the study-level relevance prediction scores for ranking. As such, TrialMind provides a rationale for the relevance scores by detailing the eligibility predictions for each criterion.

We chose MPNet⁴² and MedCPT⁴³ as the general domain and medical domain ranking baselines, respectively. These methods compute study relevance by the cosine similarity between the encoded PICO elements as the query and the encoded study's abstracts. We also set a Random baseline that randomly samples from candidates. We created the evaluation data based on the search results in the first stage. For each review, we mixed the target studies with the other found studies to build a candidate set of 2,000 studies for ranking. Discriminating the target studies from the other candidates is challenging since all candidates meet the search queries, meaning they most probably investigate the relevant therapies or conditions. We evaluated the ranking performance using the Recall@20 and Recall@50 metrics. The concatenation of the title and abstract of each study is used for all methods as inputs.

We found that TrialMind greatly improved ranking performances, with the fold changes over the best baselines ranging from 1.4 to 24 across four topics (Table 3c). For in-



Figure 3: Literature screen experiment results. **a**, Streamline study screening using TrialMind with human in the loop. **b**, Ranking performances for Recall@20/50 within across therapeutic areas. **c**, Recall@20 and Recall@50 for TrialMind and selected baselines. **d**, Effect of individual criterion on the ranking results. **e**, Ranking performance for Recall@K with varying K in four topics. Shaded areas are 95% confidence interval.

stance, for the Hormone Therapy topic, TrialMind obtained Recall@20 = 0.240 and Recall@50 = 0.439. In the Hyperthermia topic, TrialMind obtained Recall@20 = 0.246 and Recall@50 = 0.306. In the Immunotherapy topic, TrialMind obtained Recall@20 = 0.230 and Recall@50 = 0.383. In the Radiation/Chemotherapy topic, TrialMind obtained the largest advantage over baselines on the Hormone Therapy topic (fold change = 24 and 10.5 for Recall@20 and Recall@50 compared to the best baselines). In contrast, other baselines exhibit significant variability across different topics. The general domain baseline MPNet was the worst as it performed similarly to the Random baseline in Recall@20. MedCPT showed marginal improvement over MPNet in the last three topics, while both failed to capture any target studies in Hormone Therapy.

Furthermore, TrialMind demonstrated significant improvements over the baselines across various therapeutic areas (Fig. 3b). For example, in "Cancer Vaccines" and "Hormone Therapy," TrialMind substantially increased Recall@50, achieving 33.33-fold and 10.53-fold improvements, respectively, compared to the best-performing baseline. TrialMind generally attained a fold change greater than 2 (ranging from 1.57 to 33.33). Despite the challenge of selecting from a large pool of candidates (n = 2,000) where candidates were very similar, TrialMind identified an average of 43% of target studies within the top 50.

We compared TrialMind to MedCPT and MPNet for Recall@K (K in 10 to 200) to gain insight into how K influences the performances (Fig. 3e). We found TrialMind can capture most of the target studies when K = 200, as it obtained Recall@200 = 0.697 in Immunotherapy, Recall@200 = 0.618 in Radiation/Chemotherapy, Recall@200 = 0.744 in Hormone Therapy, Recall@200 = 0.830 in Hyperthermia, respectively. The improvement over baselines is especially significant in Hormone Therapy and Hyperthermia, as the other baselines did not outperform the Random performances all the time. For instance, in Hormone Therapy, MedCPT's Recall@200 = 0.122 and MPNet's Recall@200 = 0.083 (Random's Recall@200 = 0.100).

To thoroughly assess the quality of these criteria and their impact on ranking performance, we conducted a leave-one-out analysis to calculate $\Delta \text{Recall}@200$ for each criterion (Fig. 3d). The $\Delta \text{Recall}@200$ metric measures the difference in ranking performance with and without a specific criterion, with a larger value indicating superior criterion quality. Our findings revealed that most criteria positively influenced ranking performances, as the negative influence criteria are n = 1 in Hormone Therapy, n = 1 in Hyperthermia, n = 5in Radiation/Chemotherapy, and n = 7 in Immunotherapy. Additionally, we identified redundancies among the generated criteria, as those with $\Delta \text{Recall}@200 = 0$ were the most frequently observed. This redundancy likely stems from some criteria covering similar eligibility aspects, thus not impacting performance when one is omitted.

TrialMind scales data and result extraction from unstructured documents

TrialMind leverages LLMs to streamline extracting study characteristics such as target therapies, study arm design, and participants' baseline information from involved studies. Specifically, TrialMind refers to the field names and the descriptions from users and use the full content of the study documents in PDF or XML formats as inputs (Fig. 4a). When the free full content is unavailable, TrialMind accepts the user-uploaded content as the input. We developed an evaluation dataset by converting the study characteristic tables from each review paper into data points. Our dataset comprises 1,334 target data points, including 696 on study design, 353 on population features, and 285 on results. We assessed the data extraction performance using the Accuracy metric.

TrialMind demonstrated strong extraction performance across various topics (Fig. 4b): it achieved an accuracy of ACC = 0.78 (95% confidence interval (CI) = 0.75-0.81) in the Immunotherapy topic, ACC = 0.77 (95% CI = 0.72-0.82) in the Radiation/Chemotherapy topic, ACC = 0.72 (95% CI = 0.63-0.80) in the Hormone Therapy topic, and ACC = 0.83 (95% CI = 0.74-0.90) in the Hyperthermia topic. These results indicate that TrialMind can provide a solid initial data extraction, which human experts can refine. Importantly,



Figure 4: Data and result extraction experiment results. a, Streamline study information extraction using TrialMind. b, Data extraction accuracy within each field type across four topics. c, Confusion matrix showing the hallucination and missing rates in the data extraction results. d, Result extraction accuracy across topics. e, Result extraction accuracy across clinical endpoints. f, Error analysis of the result extraction. g, Streamline result extraction using TrialMind.

each output can be cross-checked by the linked original sources, facilitating verification and further investigation.

Diving deeper into the accuracy across different types of fields, we observed varying performance levels. It performed best in extracting study design information, followed by population details, and showed the lowest accuracy in extracting results (Fig. 4b). For example, in the Immunotherapy topic, TrialMind achieved an accuracy of ACC = 0.95 (95% CI = 0.92-0.96) for study design, ACC = 0.74 (95% CI = 0.67-0.80) for population data, and ACC = 0.42 (95% CI = 0.36-0.49) for results. This variance can be attributed to the prevalence of numerical data in the fields: fields with more numerical data are typically harder to extract accurately. Study design is mostly described in textual format and is directly presented in the documents, whereas population and results often include numerical data such as the number of patients or gender ratios. Results extraction is particularly challenging, often requiring reasoning and transformation to capture values accurately. Given these complexities, it is advisable to scrutinize the extracted numerical data more carefully.

We also evaluated the robustness of TrialMind against hallucinations and missing information (Fig. 4c). We constructed a confusion matrix detailing instances of hallucinations: false positives (FP) where TrialMind generated data not present in the input document and false negatives (FN) where it failed to extract available target field information. We observed that TrialMind achieved a precision of Precision = 0.994 for study design, Precision = 0.966 for population, and Precision = 0.862 for study results. Missing information was slightly more common than hallucinations, with TrialMind achieving recall rates of Recall = 0.946 for study design, Recall = 0.889 for population, and Recall = 0.930 for study results. The incidence of both hallucinations and missing information was generally low. However, hallucinations were notably more frequent in study results; this often occurred because LLMs could confuse definitions of clinical outcomes, for example, mistaking 'overall response' for 'complete response.' Nevertheless, such hallucinations are typically manageable, as human experts can easily identify and correct them while reviewing the referenced material.

The challenges in extracting study results primarily stem from (1) identifying the locations that describe the desired outcomes from lengthy papers, (2) accurately extracting relevant numerical values such as patient numbers, event counts, durations, and ratios from the appropriate patient groups, and (3) performing the correct calculations to standardize these values for meta-analysis. In response to these complexities, we developed a specialized pipeline for result extraction (Fig. 4g), where users provide the interested outcome and the cohort definition. TrialMind offers a transparent extraction workflow, documenting the sources of results along with the intermediate reasoning and calculations.

We compared TrialMind against two generalist LLM baselines, GPT-4 and Sonnet, which were prompted to extract the target outcomes from the full content of the study documents. Since the baselines can only make text extractions, we manually convert them into numbers suitable for meta-analysis.⁴⁴ This made very strong baselines since they combined LLM extraction with human post-processing. We assessed the performance using the Accuracy metric.

The evaluation conducted across four topics demonstrated the superiority of TrialMind (Fig. 4d). Specifically, in Immunotherapy, TrialMind achieved an accuracy of ACC = 0.70 (95% CI 0.62-0.77), while GPT-4 scored ACC = 0.54 (95% CI 0.45-0.62). In Radiation/Chemotherapy, TrialMind reached ACC = 0.65 (95% CI 0.51-0.76), compared to GPT-4's ACC = 0.52 (95% CI 0.39-0.65). For Hormone Therapy, TrialMind achieved ACC = 0.80 (95% CI 0.58-0.92), outperforming GPT-4, which scored ACC = 0.50 (95% CI 0.30-0.70). In Hyperthermia, TrialMind obtained an accuracy of ACC = 0.84 (95% CI 0.71-0.92), significantly higher than GPT-4's ACC = 0.52 (95% CI 0.39-0.65). The breakdowns of evaluation results by the most frequent types of clinical outcomes (Fig. 4e) showed TrialMind got fold changes in accuracy ranging from 1.05 to 2.83 and a median of 1.50 over the best baselines. This enhanced effectiveness is largely attributable to TrialMind's ability to accurately identify the correct data locations and apply logical reasoning, while the baselines often produced erroneous initial extractions.



Research question: Microwave ablation (MWA) compared with radiofrequency ablation (RFA) for the treatment of liver cancer: a systematic review and meta-analysis

а

Figure 5: Human evaluation of the synthesized clinical evidence. a, The study design compares the synthesized clinical evidence from the baseline and TrialMind via human evaluation. b, Winning rate of TrialMind against the GPT-4+Human baseline across studies. c, Violin plots of the ratings across studies. Each plot is tagged with the mean ratings (95% CI) from all the annotators. d, Violin plots of the ratings across annotators with different expertise levels. Each plot is tagged with the mean ratings (95% CI) from all the studies.

We analyzed the error cases in our result extraction experiments and identified four primary error types (Fig. 4f). The most common error was 'Inaccurate' extraction (n=36), followed by 'Extraction failure' (n=27), 'Unavailable data' (n=10), and 'Hallucinations' (n=3). 'Inaccurate' extractions often occurred due to multiple sections ambiguously describing the same field. For example, a clinical study might report the total number of participants receiving CAR-T therapy early in the document and later provide outcomes for a subset with non-small cell lung cancer (NSCLC). The specific results for NSCLC patients are crucial for reviews focused on this subgroup, yet the presence of general data can lead to confusion and inaccuracies in extraction. 'Extraction failure' and 'Unavailable data' both illustrate scenarios where TrialMind could not retrieve the information. The latter case particularly showcases TrialMind's robustness against hallucinations, as it failed to extract data outside the study's main content, such as in appendices, which were not included in the inputs. Furthermore, errors caused by hallucinations were minor. The outputs were easy to identify and correct through manual inspection since no references were provided.

TrialMind synthesizes clinical evidence from extracted results

We engaged human annotators to assess the quality of synthesized clinical evidence presented in forest plots, a format commonly used in systematic reviews to report metaanalysis results (Fig. 5a). We selected five systematic review studies as benchmarks and referenced the clinical evidence reported in the target studies. The baseline used GPT-4 with a simple prompting to extract the relevant text pieces that report the target outcome of interest (Methods). Manual calculations were necessary to standardize the data for meta-analysis. In contrast, TrialMind automated the extraction and standardization. Each annotator was asked to evaluate the evidence quality by comparing it against the evidence reported in the target review and deciding which method, TrialMind or the baseline, produced superior results. Additionally, they rated the quality of the synthesized clinical evidence on a scale of 1 to 5. The assignment of our method and the baseline was randomized to ensure objectivity.

The evaluation highlighted TrialMind's superior performance compared to the direct use of GPT-4 for clinical evidence synthesis (Fig. 5b). We calculated the winning rate of TrialMind versus the baseline across the five studies. The results indicate a consistent preference by annotators for the evidence synthesized by TrialMind over that of the baseline. Specifically, TrialMind achieved winning rates of 87.5%, 100%, 62.5%, 62.5%, and 81.2%, respectively. The baseline's primary shortcoming stemmed from the initial extraction step, where GPT-4 often failed to identify the relevant sources without well-crafted prompting. Therefore, the subsequent manual post-processing was unable to rectify these initial errors.

In addition, we illustrated the ratings of TrialMind and the baseline across studies (Fig. 5c). We found TrialMind was competent as the GPT-4+Human baseline and outperformed the baseline in many scenarios. For example, TrialMind obtained the mean rating of 4.25 (95% CI 3.93-4.57) in Study #1 while the baseline obtained 3.50 (95% CI 3.13-3.87). In Study #2, TrialMind yielded 3.50 (95% CI 3.13-3.87) while the baseline yielded 1.25 (95% CI 0.93-1.57). The performance of the two methods was comparable in the remaining three studies. These results highlight TrialMind as a highly effective alternative to conventional LLM usage in evidence synthesis, streamlining data extraction and processing while maintaining the critical benefit of human oversight.

Finally, we requested that annotators self-assess their expertise level in clinical studies, classifying themselves into three categories: 'Basic', 'Familiar', and 'Advanced'. The typical profile ranges from computer scientists at the basic level to medical doctors at the advanced level. We then analyzed the ratings given to both methods across these varying expertise levels (Fig. 5d). We consistently observed higher ratings for TrialMind than the baseline across all groups. Annotators with basic knowledge tended to provide more conservative ratings, while those with more advanced expertise offered a wider range of evaluations. For instance, the 'Basic' group provided average ratings of 3.67 (95% CI 3.34-3.39) for TrialMind compared to 3.22 (95% CI 2.79-3.66) for the baseline. The 'Advanced'

group rated TrialMind at an average of 3.40 (95% CI 3.16-3.64) and the baseline at 3.07 (95% CI 2.75-3.39).

Discussion

Clinical evidence forms the bedrock of evidence-based medicine, crucial for enhancing healthcare decisions and guiding the discovery and development of new drugs. It often comes from a systematic review of diverse studies found in the literature, encompassing clinical trials and retrospective analyses of real-world data. Yet, the burgeoning expansion of literature databases presents formidable challenges in efficiently identifying, summarizing, and maintaining the currency of this evidence.

The rapid development of large language models (LLMs) and generative AI technologies has generated considerable interest in their potential applications. However, implementing these models in a manner that is collaborative, transparent, and trustworthy poses significant challenges, especially in critical areas such as medicine.⁴⁵ For instance, when utilizing LLMs to summarize multiple studies, the summaries often merely echo the findings verbatim, omit crucial details, and fail to adhere to established best practices.⁹

This study introduces a clinical evidence synthesis pipeline enhanced by LLMs, named **TrialMind**. This pipeline is structured in accordance with established medical systematic review protocols, involving steps such as study searching, screening, data/result extraction, and evidence synthesis. At each stage, human experts have the capability to access, monitor, and modify intermediate outputs. This human oversight helps to eliminate errors and prevents their propagation through subsequent stages. Unlike approaches that solely depend on the internal knowledge of LLMs, **TrialMind** integrates human expertise through in-context learning and chain-of-thought prompting. Additionally, **TrialMind** extends external knowledge sources to its outputs through retrieval-augmented generation and leveraging external computational tools to enhance the LLM's reasoning and analytical capabilities. Comparative evaluations of **TrialMind** and traditional LLM approaches have demonstrated the advantages of this system design in LLM-driven applications within the medical field.

This study also has several limitations. First, despite incorporating multiple techniques, LLMs may still make errors at any stage. Therefore, human oversight and verification remain crucial when implementing TrialMind in practical settings. Second, the prompts used in TrialMind were developed based on prompt engineering experience, suggesting potential for performance enhancement through advanced prompt optimization or by fine-tuning the underlying LLMs to suit specific tasks better. Third, while TrialMind demonstrated effectiveness in study search, screening, and information extraction, the dataset used was limited in size due to the high costs associated with human labeling. Future research could expand on these findings with larger datasets to further validate the method's effectiveness. Fourth, the study coverage was restricted to publicly available sources from PubMed Central, which provides structured PDFs and XMLs. Many relevant studies are either not available on PubMed or are in formats that entail OCR algorithms as preprocessing, indicating a need for further engineering to incorporate broader data sources. Fifth, although TrialMind illustrated the potential of using advanced LLMs like GPT-4 to streamline clinical evidence synthesis, developing techniques to adapt the pipeline for use with other LLMs could increase its applicability. Finally, while the use of LLMs like GPT-4 can accelerate study screening and data extraction, the associated costs and processing times may present bottlenecks in some scenarios. Future enhancements that improve efficiency or utilize localized, specialized smaller models could increase practical utility.

LLMs have made significant strides in AI applications. TrialMind exemplifies a crucial aspect of system engineering in LLM-driven pipelines, facilitating the practical, robust, and transparent use of LLMs. We anticipate that TrialMind will benefit the medical AI community by fostering the development of LLM-driven medical applications and emphasizing the importance of human-AI collaboration.

Methods

Description of the TrialReviewBench Dataset

The overall flowchart for the study identification and screening process in building TrialReviewBench is illustrated in Extended Fig. 1.

Database search and initial filtering We undertook a comprehensive search on the PubMed database for meta-analysis papers related to cancer. The Boolean search terms were specifically chosen to encompass a broad spectrum of cancer-related topics. These terms included "cancer", "oncology", "neoplasm", "carcinoma", "melanoma", "leukemia", "lymphoma", and "sarcoma". Additionally, we incorporated terms related to various treatment modalities such as "therapy", "treatment", "chemotherapy", "radiation therapy", "immunotherapy", "targeted therapy", "surgical treatment", and "hormone therapy". To ensure that our search was exhaustive yet precise, we also included terms like "meta-analysis" and "systematic review" in our search criteria.

This initial search yielded an extensive pool of 46,192 results, reflecting the vast research conducted in these areas. We applied specific filters to refine these results and ensure relevance and quality. We focused on articles where PMC Full text was available and specifically categorized under "Meta-Analysis". Further refinement was done by restricting the time frame of publications to those between January 1, 2020, and January 1, 2023. We also narrowed our focus to studies conducted on humans and those available in English. This filtration process was critical in distilling the initial results into a more manageable and focused collection of 2,691 papers.

Refinement Building upon our initial search, we employed further refinement techniques using both MeSH terms and specific keywords. The MeSH terms were carefully selected to target papers precisely relevant to various forms of cancer. These terms included "cancer", "tumor", "neoplasms", "carcinoma", "myeloma", and "leukemia". This focused approach using MeSH terms effectively reduced our selection to 1,967 papers.

To further dive in on papers investigating cancer therapies, we utilized many keywords derived from the National Cancer Institute's "Types of Cancer Treatment" list. This approach was multi-faceted, with each set of keywords targeting a specific category of cancer therapy. For chemotherapy, we included terms like "chemotherapy", "chemo", and related variations. In the realm of hormone therapy, we searched for phrases such as "hormone therapy", "hormonal therapy", and similar terms. The keyword group for hyperthermia encompassed terms like "hyperthermia", "microwave", "radiofrequency", and related technologies. For cancer vaccines, we included keywords such as "cancer vaccines", "cancer vaccine", and other related terms. The search for immune checkpoint inhibitors and immune system modulators was comprehensive, including terms like "immune checkpoint inhibitors", "immunomodulators", and various cytokines and growth factors. Lastly, our search for monoclonal antibodies and T-cell transfer therapy included relevant terms like "monoclonal antibodies", "t-cell therapy", "car-t", and other related phrases.

The careful application of keyword filtering played a crucial role in narrowing down our pool of research papers to a more focused and relevant set of 352. It represents a diverse and meaningful collection of studies in cancer therapy, highlighting a range of innovative and impactful research within this field.

Manual screening of titles and abstracts Then, we manually screened titles and abstracts, applying a rigorous classification and sorting methodology. The remaining papers were first categorized based on the type of cancer treatment they explored. We then organized these papers by their citation count to gauge their impact and relevance in the field. Our selection criteria aimed to enhance the quality and relevance of our final dataset. We prioritized papers that focused on the study of treatment effects, such as safety and efficacy, of various cancer interventions. We preferred studies that compared individual treatments against a control group, as opposed to those examining the effects

of combined therapies (e.g., Therapy A+B vs. A only). To build a list of representative meta-analyses, we needed to ensure diversity in the target conditions under each treatment category.

Further, we favored studies that involved a larger number of individual studies, providing a broader base of evidence. However, we excluded network analysis studies and meta-analyses that focused solely on prognostic and predictive effects, as they did not align with our primary research focus. To maintain a balanced representation, we limited our selection to a maximum of three papers per treatment category. This process culminated in a final dataset comprising 25 papers. This curated collection forms the backbone of our analysis, ensuring a concentrated and pertinent selection of high-quality studies directly relevant to our research objectives. The characteristics of the created dataset is in Extended Table 1.

LLM Prompting

Prompting steers LLMs to conduct the target task without training the underlying LLMs. TrialMind proceeds clinical evidence synthesis in multiple steps associated with a series of prompting techniques.

In-context learning LLMs exhibit a profound ability to comprehend input requests and adhere to provided instructions during generation. The fundamental concept of incontext learning (ICL) is to enable LLMs to learn from examples and task instructions within a given context at inference time.⁵ Formally, for a specific task, we define T as the task prompt, which includes the task definition, input format, and desired output format. During a single inference session with input X, the LLM is prompted with P(T, X), where $P(\cdot)$ is a transformation function that restructures the task definition T and input X into the prompt format. The output \hat{X} is then generated as $\hat{X} = \text{LLM}(P(T, X))$.

Retrieval-augmented generation LLMs that rely solely on their internal knowledge often produce erroneous outputs, primarily due to outdated information and hallucinations. This issue can be mitigated through retrieval-augmented generation (RAG), which enhances LLMs by dynamically incorporating external knowledge into their prompts during generation.⁴⁶ We denote $R_K(\cdot)$ as the retriever that utilizes the input X to source relevant contextual information through semantic search. $R_K(\cdot)$ enables the dynamic infusion of tailored knowledge into LLMs at inference time.

Chain-of-thought Chain-of-though (CoT) guides LLMs in solving a target task in a step-by-step manner in one inference, hence handling complex or ambiguous tasks better and inducing more accurate outputs.⁴⁷ CoT employs the function $P_{\text{CoT}}(\cdot)$ to structure the task T into a series of chain-of-thought steps $\{S_1, S_2, \ldots, S_T\}$. As a result, we obtain $\{\hat{X}_S^1, \ldots, \hat{X}_S^T\} = \text{LLM}(P_{\text{CoT}}(T, X))$, all produced in a single inference session. This is rather critical when we aim to elicit the thinking process of LLM and urge it in self-reflection to improve its response. For instance, we may ask LLM to draft the initial response in the first step and refine it in the second.

LLM-driven pipeline Clinical evidence synthesis involves a multi-step workflow as outlined in the PRISMA statement.⁴¹ It can be generally outlined as identifying and screening studies from databases, extracting characteristics and results from individual studies, and synthesizing the evidence. To enhance each step's performance, task-specific prompts can be designed for an LLM to create an LLM-based module. This results in a chain of prompts that effectively addresses a complex problem, which we call LLM-driven workflow. Specifically, this approach breaks down the entire meta-analysis process into a sequence of N tasks, denoted as $\mathcal{T} = \{T_1, \ldots, T_N\}$. In the workflow, the output from one task, \hat{X}_n , serves as the input for the next, $\hat{X}_{n+1} = \text{LLM}(P(T_n, \hat{X}_n))$. This modular decomposition improves LLM performance by dividing the workflow into more manageable segments, increases transparency, and facilitates user interaction at various stages.

Incorporating these techniques, the formulation of TrialMind for any subtask can be represented as:

$$\hat{X}_{n+1} = \text{LLM}(P(T_n, X_n), R_K(X_n)), \ \forall n = 1, \dots, N,$$
(1)

where $R_K(\cdot)$ are optional.

Implementation of TrialMind

All experiments were run in Python v.3.9. Detailed software versions are: pandas v2.2.2; numpy v1.26.4; scipy v1.13.0; scikit-learn v1.4.1.post1; openai v1.23.6; langchain v0.1.16; boto3 v1.34.94; pypdf v4.2.0; lxml v5.2.1 and chromadb v0.5.0 with Python v.3.9.

LLMs We included GPT-4 and Sonnet in our experiments. GPT-4⁴⁸ is regarded as a state-of-the-art LLM and has demonstrated strong performances in many natural language processing tasks (version: gpt-4-0125-preview). Sonnet⁴⁹ is an LLM developed by Anthropic, representing a more lightweight but also very capable LLM (version: anthropic.claude-3-sonnet-20240229-v1:0 on AWS Bedrock). Both models support long context lengths (128K and 200K), enabling them to process the full content of a typical PubMed paper in a single inference session.

Research question inputs TrialMind processes research question inputs using the PICO (Population, Intervention, Comparison, Outcome) framework to define the study's topic and scope. In our experiments, the title of the target review paper served as the general description. Subsequently, we extracted the PICO elements from the paper's abstract to detail the specific aspects of the research question.

Literature search TrialMind is tailored to adhere to the established guidelines⁴¹ in conducting literature search and screening for clinical evidence synthesis. In the literature search stage, the key is formulating Boolean queries to retrieve a comprehensive set of candidate studies from databases. These queries, in general, are a combination of treatment, medication, and outcome terms, which can be generated by LLM using in-context learning. However, direct prompting can yield low recall queries due to the narrow range of user inputs and the LLMs' tendency to produce incorrect queries, such as generating erroneous MeSH (Medical Subject Headings) terms.⁶ To address these limitations, TrialMind incorporates RAG to enrich the context with knowledge sourced from PubMed, and employs CoT processing to facilitate a more exhaustive generation of relevant terms.

Specifically, the literature search component has two main steps: initial query generation and then query refinement. In the first step, TrialMind prompts LLM to create the initial boolean queries derived from the input PICO to retrieve a group of studies (Prompt in Extended Fig. 3). The abstracts of these studies then enrich the context for refining the initial queries, working as RAG. In addition, we used CoT to enhance the refinement by urging LLMs to conduct multi-step reasoning for self-reflection enhancement (Prompt in Extended Fig. 4). This process can be described as

$$\{\hat{X}_{S}^{1}, \hat{X}_{S}^{2}, \hat{X}_{S}^{3}\} = \text{LLM}(P_{\text{CoT}}(T_{\text{LS}}, X, R_{K}(X))),$$
(2)

where X denotes the input PICO; $R_K(X)$ is the set of abstracts of the found studies; $T_{\rm LS}$ is the definition of the query generation task for literature search. For the output, the first sub-step \hat{X}_S^1 indicates a complete set of terms identified in the found studies; the second \hat{X}_S^2 indicates the subset of \hat{X}_S^1 by filtering out the irrelevant; and the third \hat{X}_S^3 indicates the extension of \hat{X}_S^2 by self-reflection and adding more augmentations. In this process, LLM will produce the outputs for all three substeps in one pass, and TrialMind takes \hat{X}_S^3 as the final queries to fetch the candidate studies.

Study screening TrialMind follows PRISMA to take a transparent approach for study screening. It creates a set of eligibility criteria based on the input PICO as the basis for study selection (Prompt in Extended Fig. 5), produced by

$$\hat{X}_{\rm EC} = \text{LLM}(P(T_{\rm EC}, X)), \tag{3}$$

where $\hat{X}_{\text{EC}} = \{E_1, E_2, \dots, E_M\}$ is the *M* generated eligibility criteria; *X* is the input PICO; and T_{EC} is the task definition of criteria generation. Users are given the opportunity to modify these generated criteria, further adjusting to their needs.

Based on $\ddot{X}_{\rm EC}$, TrialMind embarks the parallel processing for the candidate studies. For *i*-th study F_i , the eligibility prediction is made by LLM as (Prompt in Extended Fig. 6)

$$\{I_i^1, \dots, I_i^M\} = \operatorname{LLM}(P(F_i, X, T_{\operatorname{SC}}, \hat{X}_{\operatorname{EC}})),$$
(4)

where T_{SC} is the task definition of study screening; F_i is the study *i*'s content; $I_i^m \in \{-1, 0, 1\}, \forall m = 1, ..., M$ is the prediction of study *i*'s eligibility to the *m*-th criterion. Here, -1 and 1 mean ineligible and eligible, 0 means uncertain, respectively. These predictions offer a convenient way for users to inspect the eligibility and select the target studies by altering the aggregation strategies. I_i^m can be aggregated to offer an overall relevance of each study, such as $\hat{I}_i = \sum_m I_i^m$. Users are also encouraged to extend the criteria set or block the predictions of some criteria to make customized rankings during the screening phase.

Data extraction Study data extraction is an open information extraction task that requires the model to extract specific information based on user inputs and handle long inputs, such as the full content of a paper. LLMs are particularly well-suited for this task because (1) they can perform zero-shot learning via in-context learning, eliminating the need for labeled training data, and (2) the most advanced LLMs can process extremely long inputs. As such, the TrialMind framework is engineered to streamline data extraction from structured or unstructured study documents using LLMs.

For the specified data fields to be extracted, TrialMind prompts LLMs to locate and extract the relevant information (Prompt in Extended Fig. 7). These data fields include (1) study characteristics such as study design, sample size, study type, and treatment arms; (2) population baselines; and (3) study findings. In general, the extraction process can be described as

$$\{\hat{X}_{\mathrm{EX}}^{1},\ldots,\hat{X}_{\mathrm{EX}}^{K}\} = \mathrm{LLM}(P(F,C,T_{\mathrm{EX}})),\tag{5}$$

where F represents the full content of a study; T_{EX} defines the task of data extraction; and $C = \{C_1, C_2, \ldots, C_K\}$ comprises the series of data fields targeted for extraction. C_k is the user input natural language description of the target field, e.g., "the number of participants in the study". The input content F is segmented into distinct chunks, each marked by a unique identifier. The outputs, denoted as $\hat{X}_{\text{EX}}^k = \{V^k, B^k\}$, include the extracted values V and the indices B that link back to their respective locations in the source content. Hence, it is convenient to check and correct mistakes made in the extraction by sourcing the origin. The extraction can also be easily scaled by making paralleled calls of LLMs.

Result extraction Our analysis indicates that data extraction generally performs well for study design and population-related fields; however, extracting study results presents challenges. Errors frequently arise due to the diverse presentation of results within studies and subtle discrepancies between the target population and outcomes versus those reported. For instance, the target outcome is the risk ratios (treatment versus control) regarding the incidence of adverse events (AEs), while the study reports AEs among many groups separately. Or, the target outcome is the incidence of severe AEs, which implicitly correspond to those with grade III and more, while the study reports all grade AEs. To overcome these challenges, we have refined our data extraction process to create a specialized result extraction pipeline that improves clinical evidence synthesis. This enhanced pipeline consists of three crucial steps: (1) identifying the relevant content within the study (Prompt in Extended Fig. 8), (2) extracting and logically processing this content to obtain numerical values (Prompt in Extended Fig. 9), and (3) converting these values into a standardized tabular format (Prompt in Extended Fig. 10).

Steps (1) and (2) are conducted in one pass using CoT reasoning as

$$\{\hat{X}_{\text{RE},S}^{1}, \hat{X}_{\text{RE},S}^{2}\} = \text{LLM}(P_{\text{CoT}}(X, O, F, T_{\text{RE}})),$$
(6)

where O is the natural language description of the clinical endpoint of interest and T_{RE} is the task definition of result extraction. In the outputs, $\hat{X}_{\text{RE},S}^1$ represents the raw content captured from the input content F regarding the clinical outcomes; $\hat{X}_{\text{RE},S}^2$ represents the elicited numerical values from the raw content, such as the number of patients in the group, the ratio of patients encountering overall response, etc. In step (3), TrialMind writes Python code to make the final calculation to convert $\hat{X}_{\text{RE},S}^2$ to the standard tabular format.

$$\hat{X}_{\text{RE}} = \exp(\text{LLM}(P(X, O, T_{\text{PY}}, \hat{X}_{\text{RE}, S}^2)), \hat{X}_{\text{RE}, S}^2).$$
(7)

In this process, **TrialMind** adheres to the instructions in $T_{\rm PY}$ to generate code for data processing. This code is then executed, using $\hat{X}_{{\rm RE},S}^2$ as input, to produce the standardized result $\hat{X}_{\rm RE}$. An example code snippet made to do this transformation is shown in Extended Fig. 2. This approach facilitates verification of the extracted results by allowing for easy backtracking to $\hat{X}_{{\rm RE},S}^1$. Additionally, it ensures that the calculation process remains transparent, enhancing the reliability and reproducibility of the synthesized evidence.

Experimental setup

Literature search and screening In our literature search experiments, we assessed performance using overall Recall, aiming to evaluate the effectiveness of different methods in identifying all relevant studies from the PubMed database using APIs.⁵⁰ For literature screening, we measured efficacy using Recall@20 and Recall@50, which gauge how well the methods can prioritize target studies at the top of the list, thereby facilitating quicker decisions about which studies to include in evidence synthesis. We constructed the ranking candidate set for each review paper by initially retrieving studies through TrialMind, then refining this list by ranking the relevance of these studies to the target review's PICO elements using OpenAI embeddings. The top 2000 relevant studies were kept. We then ensured all target papers were included in the candidate set to maintain the integrity of our groundtruth data. The final candidate set was then deduplicated to be ranked by the selected methods.

In the criteria analysis experiment, we utilized Recall@200 to assess the impact of each criterion. This was done by first computing the relevance prediction using all eligibility predictions and then recalculating it without the eligibility prediction for the specific criterion in question. The difference in Recall@200 between these two relevance predictions, denoted as Δ Recall, indicates the criterion's effect. A larger Δ Recall suggests that the criterion plays a more significant role in influencing the ranking results.

Data extraction and result extraction To evaluate performance, we measured the accuracy of the values extracted by **TrialMind** against the groundtruth. We used the study characteristic tables from the review papers as our test set. Each table's column names served as input field descriptions for **TrialMind**. We manually downloaded the full content for the studies listed in the characteristic table. To verify the accuracy of the extracted values, we enlisted three annotators who manually compared them against the data reported in the original tables.

We also measured the performance of result extraction using accuracy. The annotators were asked to carefully read the extracted results and compare them to the results reported in the original review paper. For the error analysis of **TrialMind**, the annotators were asked to check the sources to categorize the errors for one of the reasons: inaccurate, extraction failure, unavailable data, or hallucination. We designed a vanilla prompting strategy for GPT-4 and Sonnet models to set the baselines for the result extraction. Specifically, the prompt was kept minimal, as "Based on the {paper}, tell me the {outcome} from the input study for the population {cohort}", where {paper} is the placeholder for the paper's content; {outcome} is the for the target endpoint; {cohort} is the for the target population's descriptions, including conditions and characteristics. The responses from these prompts were typically in free text, from which annotators manually extracted result values to evaluate the baselines' performance.

Evidence synthesis In evidence synthesis, we processed the input data using R and the 'meta' package to make the forest plots and the pooled results based on the standardized result values. This is for both TrialMind and the baselines. Nonetheless, for the baseline, the annotators also need to manually extract the result values and standardize the values to make them ready for meta-analysis, which forms the GPT-4+Human baseline in the experiments.

We engaged two groups of annotators for our evaluation: (1) three computer scientists with expertise in AI applications for medicine, and (2) five medical doctors to assess the generated forest plots. Each annotator was asked to evaluate five review studies. For each review, we randomly presented forest plots generated by both the baseline and TrialMind. The annotators were required to determine how closely each generated plot aligned with a reference forest plot taken from the target review paper. Additionally, they were asked to judge which method, the baseline or TrialMind, produced better results in a win/lose assessment. Fig. 5a demonstrates the user interface for this study, which was created with Google Forms.



Extended Fig. 1: The flowchart of the screening process of meta-analyses involved in the MetaSyns dataset.



Extended Fig. 2: The example Python code made by TrialMind when converting the extracted result values to standardized tabular form.

Prompt for initial query generation

You are a clinical specialist. You are conducting a clinical study meta-analysis. The research is defined by the following PICO elements: P (Patient, Problem or Population): {P} I (Intervention): {I} C (Comparison): {C} O (Outcome): {O} ## Task Your task is to identify the primary clinical term(s) in this research. The clinical terms should be specific medical conditions, treatments, or procedures. General terms such as 'patients', or 'therapy' should not be included. ## Reply Format You should only reply with 1~3 primary term. Your output should be in JSON format, like this: {{ "terms": ["term1", "term2", "term3"] }}

Extended Fig. 3: Prompt for generating initial search queries in the literature search.

Prompt for query expansion and refinement
Background
You are a clinical specialist. You are conducting a clinical meta-analysis. The research is defined by the following PICO elements: P (Patient, Problem or Population): {P} I (Intervention): {} C (Comparison): {C} O (Outcome): {O}
Reference
You've already gathered these related papers: {pubmed_reference_text}
Task
Your task is to further your literature search by these 3 steps:
Step 1 Extract related term in the reference papers. Provide three lists of query terms: TREATMENTS, CONDITIONS, and OUTCOMES.
CONDITIONS: words about any conditions or disease that is related to this meta-analysis (referring to Problem section) TREATMENTS: primary related clinical terms/keywords showed in these reference papers (referring to Intervention section) OUTCOMES: clinical endpoints or outcome measurements that are related to this meta-analysis (referring to Outcome section)
Step 2 Double-check these query terms, remove the terms that is not directly related to the PICO elements of this research. Provide three lists of refined core terms: CORE_CONDITIONS, CORE_TREATMENTS, and CORE_OUTCOMES.
CORE_CONDITIONS: refined terms of conditions or disease CORE_TREATMENTS: refined terms of primary related clinical terms/keywords CORE_OUTCOMES: refined terms of clinical endpoints or outcome measurements
 ### Step 3 To expand the scope of query term searches, please extend each query term by: Synonyms and other names/forms; Possible abbreviations or full forms; Split into elements for compound phrases. Provide three lists of expanded query terms: EXPAND_CONDITIONS, EXPAND_TREATMENTS, EXPAND_OUTCOMES.
EXPAND_CONDITIONS: expanded terms of conditions or disease EXPAND_TREATMENTS: expanded terms of primary related clinical terms/keywords EXPAND_OUTCOMES: expanded terms of clinical endpoints or outcome measurements
Reply format There should be no overlap between each pair of lists
Your reply should be in a format like:
{{
"step 1": {{ "CONDITIONS": [condition1, condition2,]\\ (~10 items) "TREATMENTS": [term1, term2]\\ (~10 items) "OUTCOMES": [outcome1, outcome2,]\\ (~10 items) }
<pre>;;, \\ Refine according to P (Patient, Problem or Population): {P} and I (Intervention): {I} and O (Outcome): {O} "step 2": {{ "CORE_CONDITIONS": [condition1, condition2,] \\ (~5 items) "CORE_TREATMENTS": [term1, term2,] \\ (~5 items) "CORE_OUTCOMES" : [outcome1, outcome2] \\ (~5 items) });</pre>
<pre>\\Augmentation "step 3": {{ "EXPAND_CONDITIONS": [condition1, condition2,] \\ (~10 items) "EXPAND_TREATMENTS": [term1, term2] \\ (~10 items) "EXPAND_OUTCOMES": [outcome1, outcome2] \\ (~10 items) } }</pre>

Extended Fig. 4: Prompt for expanding and refining the initial search queries in the literature search.

1	··· - ··· ·· ·· · · · · · · · · · · · ·				
P	romnt tor	etildv		critoria	apperation
		Sluuv	Charbinty	GIRCHA	uchicialion
		,	- 0,		\mathbf{J}

You are a clinical specialist. You are conducting a clinical meta-analysis. The research is defined by the following PICO elements: P (Patient, Problem or Population): {P}

I (Intervention): {I}

C (Comparison): {C} O (Outcome): {O}

Task

Your task is to design the eligibility criteria for selecting studies for this meta-analysis study following these 3 steps:

Step 1

Based on the PRISMA guidelines and the PICO elements of this research, please identify five eligibility criteria for the studies to be included in the meta-analysis. Provide a rationale for each criterion.

ELIGIBILITY_ANALYSIS: your items and reasons here ...

Step 2

Next, create {num_title_criteria} binary questions that will help you select studies based on their titles.

These questions should be designed so that a "YES" answer indicates the study meets the criteria, while a "NO" answer means it doesn't.

The information required to answer these questions should be general and easily found in the study title.

TITLE_CRITERIA n: ...

Step 3

Finally, develop {num_abstract_criteria} more binary questions to further filter the studies based on their content.

These questions should also be designed for a "YES" or "NO" answer,

but the information required to answer them will be more detailed and is expected to be found within the main content of the study.

CONTENT_CRITERIA n: ...

Reply Format You should reply in a format like:

{{

"ELIGIBILITY_ANALYSIS": ["rationale1", "rationale12", ...] \\ the bullet points of your analysis

"TITLE_CRITERIA": ["criterion1", "criterion2", "..."] \\ the {num_title_criteria} binary title-based criteria

"CONTENT_CRITERIA": ["criterion1", "criterion2", "..."] \\ the

{num_abstract_criteria} binary content-based criteria }}

Extended Fig. 5: Prompt for study eligibility criteria generation in the literature screen.

Prompt for study eligibility assessment

CONTEXT

You are a clinical specialist tasked with assessing research papers for inclusion in a meta-analysis based on specific eligibility criteria.

OBJECTIVE

Evaluate each criterion of a given paper to determine its eligibility for inclusion in the meta-analysis. Provide a list of decisions ("YES", "NO", or "UNCERTAIN") for each eligibility criterion. You must deliver exactly {num_criteria} responses.

IMPORTANT NOTE

If the information within the provided paper content is insufficient to conclusively evaluate a criterion, you must opt for "UNCERTAIN" as your response. Avoid making assumptions or extrapolating beyond the provided data, as accurate and reliable responses are crucial, and fabricating information (hallucinations) could lead to serious errors in the meta-analysis.

PICO FRAMEWORK

- P (Patient, Problem or Population): {P}
- I (Intervention): {I}
- C (Comparison): {C}
- O (Outcome): {O}

PAPER DETAILS

- Provided Paper: {paper_content}

EVALUATION CRITERIA

- Number of Criteria: {num_criteria}
- Criteria for Inclusion: {criteria_text}

RESPONSE FORMAT

You are required to output a JSON object containing a list of decisions for each of the {num_criteria} eligibility criteria. Each decision should directly correspond to one of the criteria and be listed in the order they are presented. Ensure to use "UNCERTAIN" wherever the paper does not explicitly support a "YES" or "NO" decision. For example: ```json

```
{{
```

```
"evaluations": ["YES", "NO", "UNCERTAIN", "YES", "YES", ...] \\ List of {num_criteria} decisions
```

```
}}
```

Extended Fig. 6: Prompt for study eligibility assessment in the literature screen.

Prompt for study characteristics extraction

You are now the following python function:

def extract_fields_from_input_study(inputs: Dict[str, Any]) -> str:

This function is tasked with analyzing clinical trial study reports or papers to extract specific information as structured data

and provide citations for the extracted information.

The user will provide a list of fields they are interested in, along with a natural language description for each field to guide you on what content to look for and from which parts of the report to extract it.

IMPORTANT:

For each field described by the user, you need to:

1. Identify and extract the relevant information from the report based on the provided description.

2. Generate a field name that accurately represents the content of the field based on its description.

3. Structure the extracted information into a standard format whenever possible (e.g., integer, numerical values, dates, keywords, list of terms).

- If standardization is not possible, the information should be presented in text format.
- If the field is not found in the report, the extracted value should be "NP".
- 4. Provide a reference to the document ID from which this information was extracted.

This citation id should be restricted to be integers only.

You should NOT cite more than three sources for a single field.

You should try your best to provide the most relevant and specific citation for each field.

If two or more sources are equally relevant, you can just cite one of them.

The function returns a string representing a dictionary with each key representing a field and its extracted value. The format should be as follows:

Returns: A syntactically correct JSON string representing a list of dictionary with three keys: name, value, and source_id.

```
Format:
       `json
     [
        {{
           "name": \\ str, length <= 25 tokens
           "value": \\ str, length <= 25 tokens
           "source_id": \\ list[int], length <= 3 ids
       }},
        {{
           "name":, \\ str, length <= 25 tokens
           "value": \\ str, length <= 25 tokens
           "source_id": \\ list[int], length <= 3 ids
       }},
        ...
     j″
<u>, \"\"\</u>"
Respond exclusively with the generated JSON string wrapped ```json and ```.
# User provided inputs
paper_content = \"\"\"{paper_content}\"\"\"
fields = \"\"\"{fields}\"\"\"
inputs = {{
   "paper_content": paper_content,
   "fields": fields
}}
```

Extended Fig. 7: Prompt for study characteristics extraction in the data extraction.

```
Prompt for initial result extraction and localization
You are now the following python function: `
def locate_evidence_in_study_about_the_request_for_results(inputs: Dict[str, Any]) -> str:
  This function is tasked with analyzing clinical trial study reports or papers to extract specific information as structured data.
  Task Instructions:
  1. Review the clinical trial paper, paying close attention to the sections discussing results related to the "{target_outcome}" for the
defined cohort "{cohort}"
  2. Summarize the findings for each cohort, emphasizing the collective data and general trends observed. Individual patient data
should only be mentioned if highlighted as a significant exception or case study in the paper.
  3. Present your summary in a table format with the following columns:
  - 'Group Name': Name of the cohort.
  - 'Number of Patients': Total participants in the cohort.
    'Specified Outcome Measure': Key findings and metrics related to the "{target_outcome}".
  Include aggregate values such as percentages, mean values, and other statistical summaries that reflect the overall results for the
group.
  Must contain quantitative data, such as hazard ratios, odds ratios, mean differences, count of events, etc.
  Do not include qualitative or descriptive data that cannot be quantified, such as "statistically significant improvement" without
specific values.
  Here are the definitions of some common outcome measurements:
   - overall survival/progression-free survival/etc.: usually defined by the hazard ratio or odds ratio, which is the ratio of hazard rate or
odds of an event occurring in the treatment group to that in the control group.
     it can also be expressed as the number of events in the target group of patients.
  - toxicity/adverse events/etc.: defined by the rate of occurrence of adverse events in the target groups of patients.
  - objective response rate/overall response/etc.: defined by the proportion of patients who respond to the treatment in the target
groups, or number of patients with complete or partial response.
   - disease control rate/relapse rate/etc.: defined by the proportion of patients who have stable disease or better in the target groups,
or number of patients with disease control.
     it can also be expressed by the number of patients who have disease progression, so the disease control rate is 1 minus the
progression rate.
  Returns:
     A str representing a list of dictionary with three keys: Group Name, N, and Results.
     Group Name: str - name of the cohort
     N: int - number of participants in the cohort
     Results: str - key findings and metrics related to the outcome measure, must be quantitative and concise
       adhere to the input paper content.
     Example format:
       `ison
     [
       {{
    "Group Name": str, \\ the name of the cohort
    "mather of participants in the of

          "N": int, \\ the number of participants in the cohort
          "Results": str \\ key findings and metrics related to the outcome measure, must be quantitative and concise (<= 50 tokens)
       }}
       {{
       }},
     ]
  \"\"\"
Respond exclusively with the generated JSON string wrapped ```json and ```.
# User provided inputs
paper_content = \"\"\"{paper_content}\"\"\"
cohort = \"\"\"{cohort}\"\"\
target_outcome = \"\"\"{target_outcome}\"\"\"
inputs = {{
  "paper_content": paper_content,
   "cohort": cohort.
   "target_outcome": target_outcome
}}
```

Extended Fig. 8: Prompt for the initial result extraction in the evidence synthesis.

```
Prompt for the study result table formatting
You are now the following python function:
def format_study_result_table(inputs: Dict[str, Any]) -> str:
   This function is used to transform raw data (with the content described in texts) from a clinical study paper into a structured table format.
   IMPORTANT: Organize the extracted data into a structured table format. Ensure that each column represents a crucial numerical data
point necessary for meta-analysis. This may include participant numbers (N), measurable outcomes,
     and other quantifiable metrics related to the intervention or comparator.
   IMPORTANT: The input groups are not mutually exclusive, you need to decide whether to combine them or
     select the eligible groups based on the research question.
   IMPORTANT: Drop the group if no outcome value is provided.
   The function returns a string representing a list of dictionary, each dictionary has three keys:
    ``json
  ſ
     {{
        Group: str \\ the name of the group
        N: int \\ the number of participants in the group
        Outcome Value: float or int \\ the outcome value for the group, must be float or int values
     }},
{{
     }},
  j...
  Example output 1:
     `json
  ſ
     {{
        "Group": "Patient with irAEs",
        "N": 100,
        "Hazard Ratio": 0.5,
     }}
     {{
        "Group": "Patient without irAEs",
        "N": 150,
        "Hazard Ratio": 0.3.
     }},
  ]
  [... some more examples]
   Returns:
     A str representing a list of dictionary with three keys: Groups, N, and Outcome.
     Groups: str - the name of the group
     N: int - the number of participants in the group
     {outcome}: float or int - the outcome value for the group, must be float or int
,,, /"/"/"
Respond exclusively with the generated JSON string wrapped ```json and ```.
# User provided inputs
results = \"\"\"{results}\"\"\"
outcome = \"\"\"{outcome}\"\"\"
intervention = \"\"\"{intervention}\"\"\"
comparator = \"\"\"{comparator}\"\"\"
population = \"\"\"{population}\"\"\"
inputs = {{
   "results": results,
   "outcome": outcome,
   "intervention": intervention,
   "comparator": comparator,
   "population": population
}}
```

Extended Fig. 9: Prompt for the result formatting in the evidence synthesis.

Prompt for the study result standardization
You are now the following python function: ``` def generate_continuous_elegant_python_code(inputs: Dict[str, Any]) -> str:
Initial Content in the initial initia initial initial initial initial initial initi
The function takes a dictionary of `inputs` as an argument, which contains the following keys: - 'research_question': contains the population, intervention, comparator, and outcome (PICO) elements of the targeted meta-analysis. Based on the research question's intervention and comparator, you need to classify which arms in the raw data belong to the targeted experimental and control groups.
Based on the research question's population, you need to consider which parts of the observations in the raw data are relevant to the targeted meta-analysis. - 'raw_data': this is the markdown formatted input dataframe that contains the raw data to be transformed.
 'desc': the description of the target dataframe the generated code needs to produce. 'target_output': the generated code needs produce a dataframe follows the structure of this target_output.
IMPORTANT: 'raw_data' does **NOT** need to be parsed or loaded into a dataframe. In your generated code, just use `df` to represent the dataframe that contains the raw data.
IMPORTANT: NaN values should be treated with caution. If the raw data contains NaN values, ensure that your code handles them appropriately,
either by removing the row with any NaN values or by filling all NaN with zeros.
IMPORTANT: Never use `pd.DataFrame.append` to add data to pd.DataFrame. This method has been deprecated, and it is recommended to use `od.concat` instead.
For example, to add a new row to a dataframe, you can use `df = pd.concat([df, new_row], ignore_index=True)` Never use `df.append(new_row, ignore_index=True)`
The function returns a string of raw Python code, wrapped within <code> and </code> tags. For example: <code> # df</code>
Your generated python code here
You should implemented three functions in your code, each of which takes a dataframe as input and returns a dataframe as output: <code></code>
Dataframe definition should be ignored and not show again # df =
<pre>def classify_arms(df: pd.DataFrame): # you need to define a new column in the dataframe to indicate which group each arm belongs to # each arm should be classified as either experimental or control # e.g., `df['Group'] = ['Experimental', 'Control', 'Experimental',]` return df</pre>
def consolidate_data(df: pd.DataFrame): # consolidate the data for each group return df
def calculate_statistics(df: pd.DataFrame): # calculate the statistics for each group return df
run these functions in sequence to get the final dataframe df = classify_arms(df)
df = calculate_statistics(df)
Returns: Executable Python code that will be used to transform the raw data into the structured format. ערייין איי
Respond exclusively with the generated code wrapped <code></code> . Ensure that the code you generate is executable Python code that can be run directly in a Python environment, requiring no additional string encapsulation.
User provided inputs research_question = \"\"\"Population: {population}, Intervention: {intervention}, Comparator: {comparator}, Outcome: {outcome}\"\"\" raw_data = \"\"\"{raw_data}\"\"\" desc = \"\"\"{desc}\"\"\" target_output = \"\"\"\"{target_output}\"\"\"
inputs = {{ "research_question": research_question, "raw_data": raw_data,
"desc": desc "target_output": target_output
×**

Extended Fig. 10: Prompt for the result standardization in the evidence synthesis.

Extended Table 1: The characteristics of involved meta-analyses papers in the MetaSyns dataset. N_1 : the number of identified studies; N_2 : the number of involved studies after screening; N_3 : the number of involved participants in the studies; P: population; I/C: intervention and comparison; O: outcome measurements.

Ref	Topic	N_1	N_2	N_3	Р	I/C	0
Valle, et al. 202132	Brachytherapy	2553	150	11322	men treated with a number of salvage treatments for ra- diorecurrent prostate cancer.	Salvage radical prosta- tectomy (RP), high- intensity focused ultrasound (HIFU), cryotherapy, stereotac- tic body radiotherapy (SBRT), low-dose-rate (LDR) brachytherapy, and high-dose-rate (HDR) brachytherapy	1. 2-yr and 5-yr Relapse free survival (RFS); 2. severe gen- itourinary (GU) toxic- ity; 3. severe gastroin- testinal (GI) toxicity
Li et al. 202333	Brachytherapy	11806	15	12773	prostate cancer	(BT); 2. Brachytherapy (BT); 2. External beam radiother- apy (EBRT); 3. BT+EBRT	1. risk ratios (RRs) of genitourinary (GU) toxicity; 2. RRs of gas- trointestinal (GI) toxi- city
Hande et al. 202234	Brachytherapy	5499	24	5488	locally advanced cervi- cal cancer	 Volume-based Brachytherapy (BT); Point-A based BT 	 3-year disease- free survival (DFS); 2. 3-year local control (LC); 3. 3-year over- all survival (OS); 4. se- vere GU toxicity 5. se- vere GI toxicity
Wahyuhadi et al. 202244	Cancer Vac- cines	326	6	1202	Glioblastoma multi- forme (GBM)	1. active immunother- apy: dendritic cell vaccination, peptide vaccination, DNA vaccine, viral vector- based vaccine, antigen non-specific vaccine, autologous tumor cell therapy; 2. standard therapy (surgery, chemotherapy, radio- therapy)	 Overall survival (OS); 2. Progression- free survival (PFS); post-treatment Karnofsky perfor- mance scale (KFS); 4. serious adverse events (AEs); 5. 2-year mortality
Zhou et al. 202045	Checkpoint Inhibitors	2236	30	4971	patients with cancer receiving immune checkpoint inhibitors (ICIs): nivolumab, pembrolizumab, atezolizumab, dur- valumab, avelumab, or ipilimumab	1. occurrence of immune-related AEs (irAEs); 2. non- occurrence of irAEs	1. overall survival (OS); 2. progression- free survival (PFS)
Leone et al. 202246	Checkpoint Inhibitors	984	10	5257	advanced esophageal squamous cell carci- noma (ESCC)	immune checkpoint in- hibitors (ICIs)	1. overall survival ben- efit; 2. progression- free survival; 3. overall response rate
Song et al. 202047	Checkpoint Inhibitors	220	147	23761	cancer patients	1. anti-PD-1 & anti- PD-L1 inhibitors; 2. anti-CTLA-4 inhibitors	ICI-related AEs (Grade 1-5, Grade 3-5)
ABC Group, 202235	Chemotherapy	N/A	10	1183	participants with biopsy-proven tran- sitional cell carci- noma with muscle- invasive bladder cancer who had not received neoadjuvant chemotherapy	 adjuvant cisplatin- based chemotherapy plus local treatment; local treatment; local treatment then adjuvant cisplatin- based chemotherapy on reccurrence 	1. overall survival; 2. locoregional recurrence-free sur- vival; 3. metastasis- free survival; 4. overall recurrence-free sur- vival
Lacas et al. 202136	Chemotherapy	N/A	107	19805	squamous cell Head and Neck Cancer (MACH-NC)	Q1: 1. loco-regional treatment (LRT); 2. LRT+CT; Q2: 1. in- duction CT + radio- therapy; 2. concomi- tant CT	 overall survival; event-free survival; loco-regional failure (LRF); distant failure (DF); cancer and non-cancer mortality
Xia et al. 202037	Chemotherapy	N/A	9	36480	triple-negative breast cancer (TNBC)	1. neoadjuvant chemotherapy (NACT); 2. adju- vant chemotherapy (ACT)	 overall survival; disease-free survival (DFS)
Liu et al. 202141	Hormone Therapy	7506	16	67616	high-risk prostate can- cer (HRPCa)	1. neoadjuvant hor- mone therapy (NHT) with radical prostate- ctomy (RP); 2. RP alone	 overall sur- vival; 2. biochem- ical progression-free survival; 3. cancer- specific survival; 4. disease-free survival; 5. risk rates (RRs) of lymph node in- volvement; 6. RRs of pathological down- staging; 7. RRs of organ-confinement; 8. RRs of positive surgical margins; 9. RRs of seminal vesicle invasion

Piezzo et al. 202042	Hormone Therapy	685	8	4580	patients with HR- positive/HER2- negative advanced or metastatic breast	1. CDK4/6 inhibitors with endocrine therapy (ET); 2. ET only	1. progression-free sur- vival; 2. overall sur- vival; 3. objective re- sponse rate (ORR)
Peleg Has- son et al. 202143	Hormone Therapy	113	6	35680	cancer HR-positive/HER2- positive early-stage breast cancer	1. adjuvant endocrine therapy (tamox- ifen); 2. aromatase	disease-free survival
Kim et al. 202140	Hyperthermia	334	4	653	low-risk papillary thy- roid microcarcinomas (PTMCs)	inhibitors 1. thermal ablation; 2. surgery	1. new tumor after treatment; 2. lymph node metastasis; 3.
Wang et al. 202239	Hyperthermia	3060	9	1215	T1aN0M0 and T1bN0M0 papillary thyroid carcinoma	ultrasound-guided thermal ablation (LA, RFA, or MWA)	complication 1. volume reduction rate; 2. overall dis- easee progress rate; 3.
Spiliotis et al. 202138	Hyperthermia	716	15	2169	liver cancer	1. microwave ablation; 2. radiofrequency ab- lation	 complete ablation (CA); 2. local tumor prgression (LTP); intrahepatic distant (IDR); 4. complications
Li et al. 202048	Immune Sys- tem Modula- tors	682	9	1752	breast cancer receiving chemotherapy	1. PEGylated gran- ulocyte colony- stimulating factor (G-CSF); 2. G-CSF	1. risk ratios (RRs) of grade $\xi = 3 / 4$ neutropenia; 2. RRs of febrile neutropenia (FN); 3. time to ab- solute neutrophil count recovery; 4. grade 4 AEs; 5. RRs of skele- tal and (or muscle agin
Wu et al. 202249	Monoclonal Antibodies	116	32	958	HER2-positive pa- tients with NSCLC	HER2-targeted ther- apy	1. objective response rate (ORR); 2. disease control rate (DCR); 3. progression-free sur- vival (PFS)
Li et al. 202150	Monoclonal Antibodies	5861	27	15063	patients with solid tu- mors	1. anti-PD-1/PD-L1 mAbs; 2. anti-PD- 1/PD-L1 mAbs + chemotherapy; 3. standard chemother- apy	RR of nephrotoxicity
Zhu et al. 202351	Monoclonal Antibodies	2511	169	22492	cancer	antibody–drug conju- gates (ADCs)	1. RR of grade $i = 3$ AEs; 2. RR of all grade
Masetti et al. 202254	Stem Cell Transplant	2141	9	1448	children with pedi- atric acute myeloid leukemia (AML) in first complete remis- sion (CR1)	1. allogeneic hematopoietic stem cell transplanta- tion (allo-HSCT); 2.chemotherapy alone	1. overall survival; 2. relapse rate; 3. disease-free survival
Zeng et al. 202155	Stem Cell Transplant	499	15	959	adult philadelphia chromosome positive acute lymphoblastic leukemia in post- remission	1. allogeneic hematopoietic stem cell transplantation (allo-HSCT); 2. tyro- sine kinase inhibitor (TKI) combined with chemotherany	1. overall survival; 2. Relapse-free survival (RFS); 3. Odds Ratio of non-relapsed mor- tality (NRM); 4. Odds Ratio of non-relapsed survival (NRS)
Gagelmann et al. 202156	Stem Cell Transplant	1050	7	680	patients with FLT3- ITD-mutated acute myeloid leukemia (AML) and received allogeneic stem-cell transplation	tyrosine kinase in- hibitor (TKI) mainte- nance therapy	1. relapse-free sur- vival; 2. RRs of relapse; 3. overall survival; 4. non- replase mortality; 5. RRs of chronic graft vs. chronic disease (CVHD)
Yang et al. 202152	T-Cell Trans- fer Therapy	661	23	350	patients with Relapse or Refractory Multi- ple Myeloma (RRMM) and treated with CAR- T therapy	CAR-T therapy	 Overall response (OR); 2. complete response rate (CRR); MRD negativity within responders; relapse rate; 5. progression-free sur- vival; 6. overall sur- vival; 7. severe CRS (sCRS); 8. Neurologic
Shahzad et al. 202353	T-Cell Trans- fer Therapy	677	13	57	relapsed/refractory acute myeloid leukemia (RR-AML)	CAR-T therapy	toxicity (NT) 1. complete remission (CR); 2. overall re- sponse rate; 3. inci- dence of CRS; 4. inci- dence of ICANs; 5. in- cidence of graft-versus- host disease (GVHD)

References

- Field, A. P. & Gillett, R. How to do a meta-analysis. British Journal of Mathematical and Statistical Psychology 63, 665–694 (2010).
- [2] Borah, R., Brown, A. W., Capers, P. L. & Kaiser, K. A. Analysis of the time and workers needed to conduct systematic reviews of medical interventions using data from the prospero registry. *BMJ open* 7, e012545 (2017).
- [3] Hoffmeyer, B. D., Andersen, M. Z., Fonnes, S. & Rosenberg, J. Most cochrane reviews have not been updated for more than 5 years. *Journal of evidence-based medicine* 14, 181–184 (2021).
- [4] Marshall, I. J. & Wallace, B. C. Toward systematic review automation: a practical guide to using machine learning tools in research synthesis. *Systematic reviews* 8, 1–10 (2019).
- [5] Brown, T. et al. Language models are few-shot learners. Advances in Neural Information Processing Systems 33, 1877–1901 (2020).
- [6] Wang, S., Scells, H., Koopman, B. & Zuccon, G. Can chatgpt write a good boolean query for systematic review literature search? In Proceedings of the 46th International ACM SIGIR Conference on Research and Development in Information Retrieval, 1426–1436 (2023).
- [7] Wadhwa, S., DeYoung, J., Nye, B., Amir, S. & Wallace, B. C. Jointly extracting interventions, outcomes, and findings from rct reports with llms. In *Machine Learning* for Healthcare Conference, 754–771 (PMLR, 2023).
- [8] Syriani, E., David, I. & Kumar, G. Assessing the ability of chatgpt to screen articles for systematic reviews. arXiv preprint arXiv:2307.06464 (2023).
- [9] Shaib, C. et al. Summarizing, simplifying, and synthesizing medical evidence using gpt-3 (with varying success). In The 61st Annual Meeting Of The Association For Computational Linguistics (2023).
- [10] Wallace, B. C., Saha, S., Soboczenski, F. & Marshall, I. J. Generating (factual?) narrative summaries of RCTs: Experiments with neural multi-document summarization. *AMIA Summits on Translational Science Proceedings* **2021**, 605 (2021).
- [11] Yun, H., Marshall, I., Trikalinos, T. & Wallace, B. C. Appraising the potential uses and harms of llms for medical systematic reviews. In *Proceedings of the 2023 Conference on Empirical Methods in Natural Language Processing*, 10122–10139 (2023).
- [12] Christopoulou, S. C. Towards automated meta-analysis of clinical trials: An overview. *BioMedInformatics* 3, 115–140 (2023).
- [13] National Cancer Institute. Types of cancer treatment. https://www.cancer.gov/ about-cancer/treatment/types. Accessed: 2024-04-24.
- [14] Valle, L. F. et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (master). European urology 80, 280–292 (2021).
- [15] Li, X. et al. Comparison of chronic gastrointestinal and genitourinary toxicities between brachytherapy and external beam radiotherapy for patients with prostate cancer: A systematic review and meta-analysis. *Technology and Health Care* 1–16 (2023).
- [16] Hande, V. et al. Point-a vs. volume-based brachytherapy for the treatment of cervix cancer: A meta-analysis. Radiotherapy and Oncology 170, 70–78 (2022).
- [17] Burdett, S. et al. Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials. European urology 81, 50–61 (2022).
- [18] Lacas, B. et al. Meta-analysis of chemotherapy in head and neck cancer (mach-nc): An update on 107 randomized trials and 19,805 patients, on behalf of mach-nc group. Radiotherapy and Oncology 156, 281–293 (2021).

- [19] Xia, L.-Y., Hu, Q.-L., Zhang, J., Xu, W.-Y. & Li, X.-S. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases. World journal of surgical oncology 18, 1–8 (2020).
- [20] Spiliotis, A. E. *et al.* Microwave ablation compared with radiofrequency ablation for the treatment of liver cancer: a systematic review and meta-analysis. *Radiology and oncology* 55, 247–258 (2021).
- [21] Wang, M.-H., Liu, X., Wang, Q. & Zhang, H.-W. Safety and efficacy of ultrasoundguided thermal ablation in treating t1an0m0 and t1bn0m0 papillary thyroid carcinoma: A meta-analysis. *Frontiers in Endocrinology* 13, 952113 (2022).
- [22] Kim, H. J., Cho, S. J. & Baek, J. H. Comparison of thermal ablation and surgery for low-risk papillary thyroid microcarcinoma: a systematic review and meta-analysis. *Korean Journal of Radiology* 22, 1730 (2021).
- [23] Liu, W., Yao, Y., Liu, X., Liu, Y. & Zhang, G.-M. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis. *Asian Journal of Andrology* 23, 429–436 (2021).
- [24] Piezzo, M. et al. Progression-free survival and overall survival of cdk 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and metaanalysis. International journal of molecular sciences 21, 6400 (2020).
- [25] Hasson, S. P. et al. Adjuvant endocrine therapy in her2-positive breast cancer patients: systematic review and meta-analysis. ESMO open 6, 100088 (2021).
- [26] Wahyuhadi, J. *et al.* Active immunotherapy for glioblastoma treatment: A systematic review and meta-analysis. *Cancer Control* **29**, 10732748221079474 (2022).
- [27] Zhou, X. et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? a systematic review and metaanalysis. BMC medicine 18, 1–14 (2020).
- [28] Leone, A. *et al.* Efficacy and activity of pd-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of pd-11 combined positive score. *ESMO open* **7**, 100380 (2022).
- [29] Song, P., Zhang, D., Cui, X. & Zhang, L. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. *Thoracic cancer* 11, 2406–2430 (2020).
- [30] Li, X. et al. Is pegylated g-csf superior to g-csf in patients with breast cancer receiving chemotherapy? a systematic review and meta-analysis. Supportive Care in Cancer 28, 5085–5097 (2020).
- [31] Wu, H.-X., Zhuo, K.-Q. & Wang, K. Efficacy of targeted therapy in patients with her2-positive non-small cell lung cancer: a systematic review and meta-analysis. *British Journal of Clinical Pharmacology* 88, 2019–2034 (2022).
- [32] Li, H. et al. Nephrotoxicity in patients with solid tumors treated with anti-pd-1/pd-l1 monoclonal antibodies: a systematic review and meta-analysis. *Investigational new* drugs 39, 860–870 (2021).
- [33] Zhu, Y., Liu, K., Wang, K. & Zhu, H. Treatment-related adverse events of antibodydrug conjugates in clinical trials: A systematic review and meta-analysis. *Cancer* 129, 283–295 (2023).
- [34] Yang, Q. et al. Efficacy and safety of car-t therapy for relapse or refractory multiple myeloma: A systematic review and meta-analysis. International Journal of Medical Sciences 18, 1786 (2021).
- [35] Shahzad, M. et al. Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis. *Frontiers in Immunology* 14, 1152457 (2023).
- [36] Masetti, R., Muratore, E., Gori, D., Prete, A. & Locatelli, F. Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis. *Annals of Hematology* **101**, 2497–2506 (2022).

- [37] Zeng, Q., Xiang, B. & Liu, Z. Comparison of allogeneic hematopoietic stem cell transplantation and tki combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis. *Cancer Medicine* 10, 8741–8753 (2021).
- [38] Gagelmann, N. et al. TKI maintenance after stem-cell transplantation for flt3-itd positive acute myeloid leukemia: a systematic review and meta-analysis. Frontiers in Immunology 12, 630429 (2021).
- [39] Wu, T., Terry, M. & Cai, C. J. Ai chains: Transparent and controllable human-ai interaction by chaining large language model prompts. In *Proceedings of the 2022 CHI conference on human factors in computing systems*, 1–22 (2022).
- [40] Bodenreider, O. The unified medical language system (umls): integrating biomedical terminology. Nucleic acids research 32, D267–D270 (2004).
- [41] Page, M. J. et al. The prisma 2020 statement: an updated guideline for reporting systematic reviews. Bmj 372 (2021).
- [42] Song, K., Tan, X., Qin, T., Lu, J. & Liu, T.-Y. Mpnet: Masked and permuted pre-training for language understanding (2020). 2004.09297.
- [43] Jin, Q. et al. Medcpt: Contrastive pre-trained transformers with large-scale pubmed search logs for zero-shot biomedical information retrieval. *Bioinformatics* 39, btad651 (2023).
- [44] Deeks, J. J. & Higgins, J. P. Statistical algorithms in review manager 5. Statistical methods group of the Cochrane Collaboration 1 (2010).
- [45] Zhang, G. *et al.* Leveraging generative ai for clinical evidence synthesis needs to ensure trustworthiness. *Journal of Biomedical Informatics* 104640 (2024).
- [46] Lewis, P. et al. Retrieval-augmented generation for knowledge-intensive nlp tasks. Advances in Neural Information Processing Systems 33, 9459–9474 (2020).
- [47] Wei, J. et al. Chain-of-thought prompting elicits reasoning in large language models. Advances in neural information processing systems 35, 24824–24837 (2022).
- [48] OpenAI. Gpt-4 technical report (2024). 2303.08774.
- [49] Anthropic. Introducing the claude 3 family. https://www.anthropic.com/news/ claude-3-family (2023). Accessed: 2024-04-24.
- [50] National Center for Biotechnology Information (NCBI). Entrez programming utilities help. https://www.ncbi.nlm.nih.gov/books/NBK25501/ (2008). Accessed: 2024-04-24.